Search
Chenodeoxycholic acid
go.drugbank.com/drugs/DB06777ApprovedInvestigationalChenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. … It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones.
Foreskin keratinocyte (neonatal)
go.drugbank.com/drugs/DB10772ApprovedThe defining moment in skin culture was in 1975 when Rheinwald and Green successfully grew human keratinocytes on lethally irradiated murine fibroblasts. … Skin, the largest organ of the human body, plays the main role in protecting the body from mechanical damage. It is composed of epidermal, dermal and hypodermal layers.
Mycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigationalMycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. … [A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until
Resmetirom
go.drugbank.com/drugs/DB12914ApprovedInvestigational[L50336] Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, such as low serum thyroid hormone levels, is often observed in NAFLD. … On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD
Beremagene geperpavec
go.drugbank.com/drugs/DB17831ApprovedInvestigational[L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion. … Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB).
Ranolazine
go.drugbank.com/drugs/DB00243ApprovedInvestigational[L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440] … Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities.
Benserazide
go.drugbank.com/drugs/DB12783ApprovedInvestigationalWhen levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the … combination in the form of levodopa and carbidopa.
Evinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigational[A229273] Loss-of-function mutations in _ANGPTL3_ have been noted to result in hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with … Evinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH.
Trospium
go.drugbank.com/drugs/DB00209ApprovedInvestigational[L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211] … Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably.
Ocrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigationalIt was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. … In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a].